' '
Deutsch | English    

Forschungsdatenbank PMU-SQQUID

Cerebral venous thrombosis and severe acute respiratory syndrome coronavirus-2 infection: A systematic review and meta-analysis.
Baldini, T; Asioli, GM; Romoli, M; Dias, MC; Schulte, EC; Hauer, L; De Sousa, DA; Sellner, J; Zini, A
Eur J Neurol. 2021; 28(10):3478-3490
Übersichtsarbeiten

PMU-Autor/inn/en

Sellner Larissa

Abstract

BACKGROUND AND PURPOSE
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection predisposes patients to arterial and venous thrombosis. This study aimed to systematically review the available evidence in the literature for cerebral venous thrombosis (CVT) in association with coronavirus disease-2019 (COVID-19).
We searched MEDLINE, Embase, and Cochrane Central Register of Controlled Trials databases to identify cases of COVID-19-associated CVT. The search period spanned 1 January 2020 to 1 December 2020, and the review protocol (PROSPERO-CRD42020214327) followed Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Identified studies were evaluated for bias using the Newcastle-Ottawa scale. A proportion meta-analysis was performed to estimate the frequency of CVT among hospitalized COVID-19 patients.
We identified 57 cases from 28 reports. Study quality was mostly classified as low. CVT symptoms developed after respiratory disease in 90%, and the mean interval was 13 days. CVT involved multiple sites in 67% of individuals, the deep venous system was affected in 37%, and parenchymal hemorrhage was found in 42%. Predisposing factors for CVT beyond SARS-CoV-2 infection were present in 31%. In-hospital mortality was 40%. Using data from 34,331 patients, the estimated frequency of CVT among patients hospitalized for SARS-CoV-2 infection was 0.08% (95% confidence interval [CI]: 0.01-0.5). In an inpatient setting, CVT accounted for 4.2% of cerebrovascular disorders in individuals with COVID-19 (cohort of 406 patients, 95% CI: 1.47-11.39).
Cerebral venous thrombosis in the context of SARS-CoV-2 infection is a rare, although there seems to be an increased relative risk. High suspicion is necessary, because the diagnosis of this potentially life-threatening condition in COVID-19 patients can be challenging. Evidence is still scarce on the pathophysiology and potential prevention of COVID-19-associated CVT.


Useful keywords (using NLM MeSH Indexing)

COVID-19*

Cohort Studies

Humans

Intracranial Thrombosis*/epidemiology

SARS-CoV-2

Venous Thrombosis*/epidemiology


Find related publications in this database (Keywords)

cerebral venous sinus thrombosis
cerebral venous thrombosis
coronavirus
COVID-19
intracranial complication
intracranial sinus thrombosis
SARS-CoV-2